- Home
- NJR vs FOLD Comparison
NJR vs FOLD Comparison
Compare NJR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NJR | FOLD |
|---|---|---|
| Founded | 1922 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | 1994 | 2006 |
Fundamental Metrics
Financial Performance| Metric | NJR | FOLD |
|---|---|---|
| Price | $55.55 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $53.75 | $27.25 |
| AVG Volume (30 Days) | 386.9K | ★ 2.5M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | 14.04 | ★ 50.00 |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $1,351,305,000.00 | N/A |
| Revenue This Year | $11.42 | $20.50 |
| Revenue Next Year | $2.12 | $18.59 |
| P/E Ratio | $46.37 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $43.46 | $5.66 |
| 52 Week High | $57.70 | $14.50 |
Technical Indicators
Market Signals| Indicator | NJR | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 50.67 | 74.18 |
| Support Level | $54.88 | $14.21 |
| Resistance Level | $57.70 | N/A |
| Average True Range (ATR) | 0.89 | 0.02 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 27.38 | 100.00 |
Price Performance
Historical ComparisonAbout NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.